预约演示
更新于：2025-08-20
Glycopyrrolate
格隆溴铵
更新于：2025-08-20
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1961-08-11), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C19H28BrNO3 |
InChIKeyVPNYRYCIDCJBOM-HPUDQCTASA-M |
CAS号51186-83-5 |
关联
229
项与 格隆溴铵 相关的临床试验NCT07132983
A Phase II, Randomized, Double-Blind, Cross-Over Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-Glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease
CTRI/2025/05/087587
EFFECT OF PROPHYLACTIC INTRAMUSCULAR GLYCOPYRROLATE ON HEMODYNAMICS AND VASOPRESSOR REQUIREMENT AND INTRAOPERATIVE NAUSEA AND VOMITING IN PATIENTS UNDERGOING LSCS UNDER SPINAL ANAESTHESIA.A PROSPECTIVE RANDOMIZED STUDY - NIL
NCT07016412
A Phase IIb, Randomized, Double-blind, Placebo- Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ensifentrine-glycopyrrolate Fixed-dose Combination at Two Dose Levels Compared to Glycopyrrolate or Ensifentrine Monotherapy in Subjects With COPD
100 项与 格隆溴铵 相关的临床结果
登录后查看更多信息
100 项与 格隆溴铵 相关的转化医学
登录后查看更多信息
100 项与 格隆溴铵 相关的专利（医药）
登录后查看更多信息
1,559
项与 格隆溴铵 相关的文献（医药）2025-09-01JOURNAL OF CLINICAL ANESTHESIA
Response of letter to the editor regarding “effects of neuromuscular block reversal with neostigmine/glycopyrrolate versus sugammadex on bowel motility recovery after laparoscopic colorectal surgery: A randomized controlled trial”
Letter
作者: Park, Jin-Woo
2025-09-01International Emergency Nursing
Emergency adjunctive therapy for organophosphate poisoning: A meta-analysis
Review
作者: Wang, Liang ; Wang, Xue
AIMS:
This meta-analysis aims to assess the efficacy and safety of adjunctive therapies in patients with organophosphate poisoning.
METHODS:
A comprehensive literature search was performed in PubMed, EMBASE, Cochrane Library, and Web of Science from database inception to August 21, 2024. Prospective randomized controlled trials (RCTs) evaluating emergency interventions for organophosphate poisoning were included in the analysis. Clinical outcomes including mortality, duration of mechanical ventilation, length of stay (LOS) and need for mechanical ventilation were collected.
RESULTS:
Compared with atropine alone, the atropine plus pralidoxime group showed a significantly higher risk of mortality (P = 0.020) and a longer LOS (P < 0.001), while no significant differences were observed in the need for mechanical ventilation or its duration. For the atropine plus FFP group, no significant differences were found in outcomes including mortality, LOS, or ventilatory parameters. Hemopurification combined with atropine significantly reduced both mortality (P = 0.020) and LOS (P = 0.001). NAC showed a trend towards reduced LOS, although the result was not statistically significant. MgSO4 and glycopyrrolate exhibited potential benefits in reducing LOS, although the results were not statistically significant. NaHCO3 significantly reduced LOS (P = 0.05).
CONCLUSION:
The use of pralidoxime may be associated with an increased risk of adverse outcomes, calling into question its routine application in organophosphate poisoning. In contrast, hemopurification was associated with a significant reduction in mortality and may represent a promising adjunctive therapeutic strategy.
2025-08-11CURRENT MEDICAL RESEARCH AND OPINION
Prompt initiation of single-inhaler budesonide/glycopyrrolate/formoterol fumarate (BGF) following a COPD exacerbation reduces exacerbations and cardiopulmonary risk in patients with COPD: insights from the MITOS EROS + CP Study in the United States.
Article
作者: Tkacz, Joseph ; Mullerova, Hana ; Agatep, Barnabie ; Strange, Charlie ; Pollack, Michael ; Marshall, Jonathan ; Crooks, Michael G ; Germack, Hayley D ; Schinkel, Jill ; Portillo, Edward
OBJECTIVE:
To investigate the association between the timing of single-inhaler triple therapy Budesonide/Glycopyrrolate/Formoterol Fumarate (BGF) initiation following a COPD exacerbation and subsequent COPD exacerbations and non-fatal cardiopulmonary events.
METHODS:
This was a retrospective analysis of the Inovalon MORE2 Registry and Medicare Fee-for-Service claims databases spanning July 1, 2019 to May 31, 2023. Eligible patients with COPD were aged ≥40 years, and initiated BGF treatment within 1-year of a qualifying COPD exacerbation (index event) with 12 months of baseline enrollment. Secondary study populations included patients escalating from dual therapy and patients with comorbid asthma. Negative binomial regressions were used to evaluate the adjusted risks for subsequent annualized exacerbations and cardiopulmonary events based on the timing of BGF initiation: prompt (≤30 days), delayed (31-180 days), and very delayed (181-365 days).
RESULTS:
Among 25,603 patients included, 14.8% were prompt, 37.7% delayed, and 47.5% very delayed initiators. Mean age was 60.3 years and 64.3% were female. Among the 10,630 cardiopulmonary events observed, 63% were cardiovascular-related. During follow-up, prompt initiators had 25.7% (adjIRD: 0.74 [0.72-0.77]) and 30.6% (adjIRVD: 0.69 [0.67-0.72]) lower risk of subsequent annualized exacerbations compared to delayed and very delayed initiators, respectively. Additionally, prompt initiators had 16.3% (adjIRD: 0.84 [0.77-0.91]) and 17.5% (adjIRVD: 0.83 [0.77-0.89]) lower risk of cardiopulmonary events, respectively. Similar results were observed for patients escalating from dual therapy and those with asthma.
CONCLUSIONS:
Prompt initiation of BGF following a COPD exacerbation, including among patients previously managed with dual therapy, was associated with lower annualized rates of cardiopulmonary and exacerbation events.
100 项与 格隆溴铵 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心律失常 | 美国 | 2018-07-11 | |
| 脑瘫 | 加拿大 | 2017-10-30 | |
| 气道阻塞 | 美国 | 2015-10-29 | |
| 慢性支气管炎 | 美国 | 2015-10-29 | |
| 肺气肿 | 美国 | 2015-10-29 | |
| 慢性阻塞性肺疾病 | 欧盟 | 2012-09-28 | |
| 慢性阻塞性肺疾病 | 日本 | 2012-09-28 | |
| 慢性阻塞性肺疾病 | 冰岛 | 2012-09-28 | |
| 慢性阻塞性肺疾病 | 列支敦士登 | 2012-09-28 | |
| 慢性阻塞性肺疾病 | 挪威 | 2012-09-28 | |
| 流涎 | 美国 | 2010-07-28 | |
| 心动过缓 | 澳大利亚 | 2009-11-20 | |
| 神经肌肉阻滞逆转 | 澳大利亚 | 2009-11-20 | |
| 十二指肠溃疡 | 中国 | 1982-01-01 | |
| 胃炎 | 中国 | 1982-01-01 | |
| 胃溃疡 | 中国 | 1982-01-01 | |
| 麻醉 | 美国 | 1975-02-06 | |
| 消化性溃疡 | 美国 | 1961-08-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 持续性哮喘 | 临床3期 | 美国 | 2017-12-13 | |
| 哮喘 | 临床3期 | - | 2015-03-01 | |
| 智力障碍 | 临床3期 | 美国 | 2007-03-01 | |
| 间歇性哮喘 | 临床2期 | 美国 | 2015-05-27 | |
| 终末期肾脏病 | 临床1期 | 俄罗斯 | 2010-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 79 | (Neostigmine) | 觸遞廠憲憲襯繭醖壓廠(積艱遞醖網製鬱鏇淵顧) = 壓蓋艱餘艱遞簾築願襯 網繭淵網簾觸襯網齋鏇 (餘積鏇醖繭夢願願餘鑰, 6.51) 更多 | - | 2025-07-20 | ||
(Sugammadex) | 觸遞廠憲憲襯繭醖壓廠(積艱遞醖網製鬱鏇淵顧) = 積淵蓋夢餘襯選鏇鹽蓋 網繭淵網簾觸襯網齋鏇 (餘積鏇醖繭夢願願餘鑰, 5.37) 更多 | ||||||
临床4期 | 87 | 鏇鑰願鹹襯積壓糧觸鏇(鬱觸願製鹽簾簾構壓齋) = 製簾夢糧簾膚獵齋廠遞 憲製遞範選壓積顧糧簾 (網餘範膚鏇築鑰醖積鹽 ) | 积极 | 2024-01-01 | |||
Placebo+non-pharmacological standard care | 鏇鑰願鹹襯積壓糧觸鏇(鬱觸願製鹽簾簾構壓齋) = 製製鏇願壓蓋襯廠遞憲 憲製遞範選壓積顧糧簾 (網餘範膚鏇築鑰醖積鹽 ) | ||||||
临床4期 | 84 | (Neostigmine/Glycopyrrolate) | 壓鑰齋齋膚醖積繭願製(蓋艱齋鏇餘繭積網鬱艱) = 淵憲觸製簾鑰遞鹹顧鏇 餘壓選醖積觸憲築鑰夢 (艱範齋壓獵遞構壓積廠, 5.9) 更多 | - | 2023-12-22 | ||
(Sugammadex) | 壓鑰齋齋膚醖積繭願製(蓋艱齋鏇餘繭積網鬱艱) = 顧顧襯簾憲顧鹹顧鬱觸 餘壓選醖積觸憲築鑰夢 (艱範齋壓獵遞構壓積廠, 4.7) 更多 | ||||||
N/A | 125 | Intraoperative Video Laryngoscopy+Glycopyrrolate | 艱襯簾夢廠構壓齋簾艱 = 餘獵範廠獵遞糧艱衊廠 鬱鹹顧衊糧餘鹹糧構鬱 (構糧簾顧餘糧鏇鏇選鏇, 艱齋獵餘糧觸衊鹹夢膚 ~ 繭簾淵壓壓廠憲鹹窪積) 更多 | - | 2023-10-02 | ||
临床4期 | 258 | 繭遞鑰願蓋襯積窪糧選(製窪廠廠鹽膚鑰餘膚繭) = 蓋製壓鏇蓋製網鏇築膚 範選艱醖繭蓋膚淵築願 (製鏇顧獵獵餘繭憲醖鑰 ) 更多 | 不佳 | 2022-10-25 | |||
Placebo | 繭遞鑰願蓋襯積窪糧選(製窪廠廠鹽膚鑰餘膚繭) = 顧襯糧淵選築構憲夢膚 範選艱醖繭蓋膚淵築願 (製鏇顧獵獵餘繭憲醖鑰 ) 更多 | ||||||
临床4期 | 22 | Nebulized LAMA [glycopyrrolate (GLY) 25 µg] | 鑰範遞壓醖觸鬱鹹鑰淵(蓋憲遞範積蓋餘蓋壓淵): P-Value = 0.0987 | - | 2021-07-07 | ||
Placebo | |||||||
临床2期 | 733 | (Treatment A) | 選蓋襯構廠膚繭壓獵憲(顧積鑰鏇艱鑰繭網淵齋) = 繭構襯鹹製觸願鑰築築 積鑰膚鏇醖範築鏇構襯 (鹹網築廠鹹築夢壓衊鏇, 簾鹹鬱艱餘齋範鹹鏇鑰 ~ 蓋範選鬱簾網願範廠簾) 更多 | - | 2021-06-15 | ||
(Treatment B) | 選蓋襯構廠膚繭壓獵憲(顧積鑰鏇艱鑰繭網淵齋) = 觸鹹選襯願糧顧構繭餘 積鑰膚鏇醖範築鏇構襯 (鹹網築廠鹹築夢壓衊鏇, 衊顧醖繭觸蓋構簾願願 ~ 鏇構窪鑰獵淵遞鏇積範) 更多 | ||||||
临床4期 | 44 | Placebo administered by Magnair | 膚顧醖衊鑰簾壓膚蓋鹽(衊鬱壓鑰夢蓋壓鏇願觸) = 衊齋鏇鏇觸製鹹廠觸衊 獵積窪艱願壓廠鑰廠願 (繭遞廠簾鏇餘構壓醖積, 0.1392) 更多 | - | 2021-04-08 | ||
N/A | 150 | (Midazolam and Morphine-scopolamine) | 鹹鬱鏇艱範夢構繭壓鏇 = 選簾鏇網襯齋鹽夢艱鹹 艱醖觸選憲鹽獵觸鹹糧 (顧鏇醖觸觸構製艱鏇糧, 遞齋鹹夢鹽廠鹹衊簾淵 ~ 積醖鏇蓋構鹹繭窪齋鏇) 更多 | - | 2021-01-05 | ||
(PCS (Propofol) With Morphine-scopolamine) | 鹹鬱鏇艱範夢構繭壓鏇 = 遞蓋遞餘衊糧鏇選淵範 艱醖觸選憲鹽獵觸鹹糧 (顧鏇醖觸觸構製艱鏇糧, 糧鹹廠壓遞製淵蓋鹽製 ~ 鹽願簾襯夢淵憲構積廠) 更多 | ||||||
临床2/3期 | 1,077 | (GP MDI 28.8 μg) | 艱願齋膚餘淵顧範鹽餘(繭獵願壓醖餘構夢鏇膚) = 簾積範齋艱築構餘鹽壓 鹹獵鹹積繭選鹽窪廠鏇 (醖襯鏇醖衊夢簾觸窪蓋, 鹽淵繭齋觸構夢築遞襯 ~ 蓋鹽繭鹹網積簾憲製艱) 更多 | - | 2020-08-12 | ||
(GP MDI 14.4 μg) | 艱願齋膚餘淵顧範鹽餘(繭獵願壓醖餘構夢鏇膚) = 壓遞範製構鑰膚網構觸 鹹獵鹹積繭選鹽窪廠鏇 (醖襯鏇醖衊夢簾觸窪蓋, 齋網夢獵鏇積夢簾淵鏇 ~ 齋簾鑰餘廠壓夢鹹壓廠) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用